A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Duvelisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Sep 2018 According to Verastem Oncology media release, company announced dosing of the first patient in this study.
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.
- 28 May 2018 New trial record